Stay updated on NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial

Sign up to get notified when there's something new on the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The REVEAL study record is displayed with details on its terminated status, study design, eligibility, locations, interventions, outcomes, and posted results. It also includes a publication and study documents, including the protocol and statistical analysis plan.
    Difference
    69%
    Check dated 2026-11-07T11:48:06.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The site footer now identifies revision v3.8.0 instead of v3.7.2; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T12:17:56.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A site-wide banner announces that NIH is transitioning to use “Super Intelligence” instead of “Artificial Intelligence,” with updates and FAQs available.
    Difference
    1%
    Check dated 2026-10-24T12:07:59.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.1 to v3.7.2. The study record remains inaccessible behind a 403 error.
    Difference
    0.2%
    Check dated 2026-10-17T12:43:07.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The site revision displayed in the page footer changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-10T12:58:40.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error for the study record. The prior list of documents and related metadata appears removed or hidden, indicating an access-restriction state.
    Difference
    20%
    Check dated 2026-09-19T19:34:10.000Z thumbnail image

Stay in the know with updates to NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the NKTR-262 Combo + Nivolumab in Solid Tumors Clinical Trial page.